Zentalis Pharmaceuticals, Inc. 8-K

What Happened
Zentalis Pharmaceuticals, Inc. filed a Form 8‑K on April 17, 2026 (Regulation FD disclosure) stating the company issued a press release and is presenting scientific posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. The press release is furnished as Exhibit 99.1 to the filing, and the posters are furnished as Exhibits 99.2 and 99.3.

Key Details

• Filing date: April 17, 2026 (Form 8‑K, Item 7.01, Regulation FD disclosure).
• Event: AACR Annual Meeting, April 17–22, 2026, San Diego, CA.
• Exhibits: Press release (Exhibit 99.1) and two posters (Exhibits 99.2 and 99.3) are incorporated by reference in the 8‑K.
• Item noted: Exhibit filings also listed under Item 9.01 (financial statements and exhibits).

Why It Matters
This 8‑K informs investors that Zentalis is publicly sharing information (via a press release) and presenting scientific data at a major oncology conference, which can affect visibility with researchers, clinicians, and the investment community. The filing satisfies Regulation FD disclosure requirements by making those materials publicly available; investors should review the referenced exhibits for any new clinical or corporate details.